Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (14)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Schulz, W.A.
Right arrow Articles by Cronauer, M.V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schulz, W.A.
Right arrow Articles by Cronauer, M.V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Molecular Human Reproduction, Vol. 9, No. 8, 437-448, August 2003
© 2003 European Society of Human Reproduction and Embryology

Article

Molecular biology of prostate cancer

Submitted on March 14, 2003; accepted on May 8, 2003

W.A. Schulz1, M. Burchardt and M.V. Cronauer

Department of Urology, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225 Düsseldorf, Germany

1 To whom correspondence should be addressed. e-mail: wolfgang.schulz{at}uni-duesseldorf.de

In spite of progress in diagnosis and treatment, prostate cancer has become one of the most frequent lethal cancers in males in many Western industrialized countries. Research on the molecular biology of prostate cancer is expected to reveal those aspects of Western lifestyle contributing to its high incidence with the aims of improving prevention, distinguishing slow-growing from aggressive clinically relevant cancers, and providing targets for treatment, particularly of locally advanced and of metastatic disease. Traditionally, prostate cancer research focused on androgens. More recently, tumour suppressors and proto-oncogenes important in other human cancers have been intensely investigated. Current approaches include the search for genes mutated in familial cases, identification of recurrent chromosomal alterations and their associated potential tumour suppressor genes, determination of gene expression profiles characterizing tumour stages and subclasses, and elucidation of the importance of epigenetic alterations. Results from such studies have begun to be translated into the clinic. Further successful transfer of results from molecular biology to the clinic will, however, require integration of the amassed molecular data into a biological framework model of prostate carcinoma.

Key words: androgens/epigenetics/expression profiling/oncogene/tumour suppressor


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
R. Ilagan, L. J. Zhang, J. Pottratz, K. Le, S. Salas, M. Iyer, L. Wu, S. S. Gambhir, and M. Carey
Imaging androgen receptor function during flutamide treatment in the LAPC9 xenograft model
Mol. Cancer Ther., November 1, 2005; 4(11): 1662 - 1669.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
R. Kindich, A. R. Florl, V. Jung, R. Engers, M. Muller, W. A. Schulz, and B. Wullich
Application of a Modified Real-Time PCR Technique for Relative Gene Copy Number Quantification to the Determination of the Relationship between NKX3.1 Loss and MYC Gain in Prostate Cancer
Clin. Chem., March 1, 2005; 51(3): 649 - 652.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.